Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB06151> ?p ?o ?g. }
Showing items 1 to 25 of
25
with 100 items per page.
- drugbank:DB06151 type drugbank_vocabulary:Drug assertion.
- drugbank:DB06151 label "Acetylcysteine [drugbank:DB06151]" assertion.
- drugbank:DB06151 seeAlso DB06151 assertion.
- drugbank:DB06151 seeAlso acetylcysteine-solution.html assertion.
- drugbank:DB06151 seeAlso acetylcysteine.htm assertion.
- drugbank:DB06151 identifier "drugbank:DB06151" assertion.
- drugbank:DB06151 description "Acetylcysteine (also known as N-acetylcysteine or N-acetyl-L-cysteine or NAC) is primarily used as a mucolytic agent and in the management of acetaminophen poisoning. It is a derivative of cysteine with an acetyl group attached to the amino group of cysteine. NAC is essentially a prodrug that is converted to cysteine (in the intestine by the enzyme aminoacylase 1) and absorbed in the intestine into the blood stream. Cysteine is a key constituent to glutathione and hence administration of acetylcysteine replenishes glutathione stores. Acetylcysteine can also be used as a general antioxidant which can help mitigate symptoms for a variety of diseases exacerbated by reactive oxygen species (ROS). For instance, acetylcysteine is commonly used in individuals with renal impairment to prevent the precipitation of acute renal failure. Acetylcysteine has been shown to have efficacy in treating mild to moderate traumatic brain injury including ischemic brain injury, particularly in reducing neuronal losses, and also reducing cognitive and neurological symptoms when administered promptly after injury. N-acetylcysteine is now widely used in the treatment of HIV, and it has reported efficacy in chronic obstructive pulmonary disease and contrast-induced nephropathy. Acetylcysteine is also being successfully used to treat a variety of neuropsychiatric and neurodegenerative disorders including cocaine, cannabis, and smoking addictions, Alzheimer's and Parkinson's diseases, autism, compulsive and grooming disorders, schizophrenia, depression, and bipolar disorder. Recent data also shows that N-acetylcysteine inhibits muscle fatigue and can be used to enhance performance in endurance events and in exercise and endurance training." assertion.
- drugbank:DB06151 title "Acetylcysteine" assertion.
- drugbank:DB06151 bio2rdf_vocabulary:identifier "DB06151" assertion.
- drugbank:DB06151 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB06151 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB06151" assertion.
- drugbank:DB06151 bio2rdf_vocabulary:x-identifiers.org DB06151 assertion.
- drugbank:DB06151 drugbank_vocabulary:drugbank-id "DB06151" assertion.
- drugbank:DB06151 drugbank_vocabulary:x-cas cas:616-91-1 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-chemspider chemspider:11540 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-pdb pdb:SC2 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-pubchemcompound pubchem.compound:12035 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:99443235 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-chebi chebi:28939 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-dpd dpd:2091526 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-kegg kegg:C06809 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-kegg kegg:D00221 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-pharmgkb pharmgkb:PA448033 assertion.
- drugbank:DB06151 drugbank_vocabulary:x-wikipedia wikipedia:Acetylcysteine assertion.
- drugbank:DB06151 drugbank_vocabulary:x-ndc ndc:0517-7604-25 assertion.